Andre Hoekema
Vorsitzender bei Artax Biopharma, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Paulus Stoffels | M | 62 | 2 Jahre | |
Jos Joore | M | - |
Mimetas BV
Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | 11 Jahre |
Carulla Tormo | M | - |
Artax Biopharma, Inc.
Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | - |
Paul Vulto | M | - |
Mimetas BV
Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | 11 Jahre |
Rob W. Armstrong | M | 67 |
Artax Biopharma, Inc.
Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | 11 Jahre |
Alan Walts | M | 64 |
Artax Biopharma, Inc.
Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | 7 Jahre |
Linda Higgins | M | 62 | 5 Jahre | |
Lena Elisabeth Svanberg | M | 63 | 4 Jahre | |
Dan Baker | M | 74 | 2 Jahre | |
Peter Guenter | M | 61 | 5 Jahre | |
Jeanne Bolger | M | - |
Sapreme Technologies BV
Sapreme Technologies BV BiotechnologyHealth Technology Sapreme Technologies BV operates as a biotech company that develops a platform technology to enable cytosolic delivery of macromolecule therapeutics. The company was founded by Ruben Postel in 2016 and is headquartered in Utrecht, the Netherlands. | 1 Jahre |
Jérôme Contamine | M | 66 | 2 Jahre | |
Ruben Postel | M | - |
Sapreme Technologies BV
Sapreme Technologies BV BiotechnologyHealth Technology Sapreme Technologies BV operates as a biotech company that develops a platform technology to enable cytosolic delivery of macromolecule therapeutics. The company was founded by Ruben Postel in 2016 and is headquartered in Utrecht, the Netherlands. | 8 Jahre |
Bas Trietsch | M | - |
Mimetas BV
Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | - |
Andres Gagete | M | - |
Artax Biopharma, Inc.
Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | - |
Jacquelien ten Dam | F | - |
Mimetas BV
Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | - |
Annelies Missotten | F | 52 | 6 Jahre | |
Edward Willems | M | - |
Mimetas BV
Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | - |
Gino Santini | M | 67 |
Artax Biopharma, Inc.
Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | 10 Jahre |
Sofie van Gijsel | F | - | 6 Jahre | |
Eric van der Putten | M | - |
Mimetas BV
Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | - |
Sandra Cauwenberghs | M | - | 4 Jahre | |
Daniel Geffken | M | 67 |
Artax Biopharma, Inc.
Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | - |
Raf Hofstein | M | 75 |
Fibrocor Therapeutics LP
Fibrocor Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety. | - |
Marieke Vermeersch | F | - | 3 Jahre | |
Cynthia Lavoie | M | - |
Fibrocor Therapeutics LP
Fibrocor Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety. | - |
Herbert L. Heyneker | M | - |
Mimetas BV
Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | - |
Valeria Cnossen | F | 51 | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Joseph Lobacki | M | 65 |
Artax Biopharma, Inc.
Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | 4 Jahre |
Onno van de Stolpe | M | 64 | 23 Jahre | |
Bart Filius | M | 54 | 9 Jahre | |
Vicki Sato | M | 75 | 3 Jahre | |
Mary Kerr | M | 63 | 7 Jahre | |
Christine Mummery | M | 70 | - | |
Paul van der Horst | M | - | - | |
Piet Wigerinck | M | 58 | 13 Jahre | |
Elizabeth Goodwin | F | - | - | |
Daniel O'Day | M | 59 | 5 Jahre | |
Howard Mitchell Rowe | M | 55 | 12 Jahre | |
Rudi Pauwels | M | 65 | 11 Jahre | |
Harrold van Barlingen | M | 58 | 13 Jahre | |
Björn Cochlovius | M | 56 |
Sapreme Technologies BV
Sapreme Technologies BV BiotechnologyHealth Technology Sapreme Technologies BV operates as a biotech company that develops a platform technology to enable cytosolic delivery of macromolecule therapeutics. The company was founded by Ruben Postel in 2016 and is headquartered in Utrecht, the Netherlands. | 4 Jahre |
Ferdinand Verdonck | M | 81 | 8 Jahre | |
Werner Cautreels | M | 71 | - | |
Katrine Bosley | F | 56 | 9 Jahre | |
Ronald H. P. Brus | M | 61 | 11 Jahre | |
Michele Manto | M | - | 6 Jahre | |
Carmen Vroonen | F | - | 2 Jahre | |
Walid Abi-Saab | M | 59 | 5 Jahre | |
Wilson Totten | M | 68 | - | |
Radan Spaventi | M | - | - | |
Guillaume Jetten | M | 52 | 5 Jahre | |
Graham Dixon | M | 63 | 8 Jahre | |
Henry Geoffrey McMillan | M | - | - | |
Leo Steenbergen | M | 71 | 2 Jahre | |
William Rapeport | M | - | - | |
David Smith | M | 58 | 1 Jahre | |
Christopher Gregory Newton | M | 68 | 7 Jahre | |
David Stone | M | - | - | |
Laurent Gerard Ganem | M | 66 | - | |
Karen LaRochelle | F | 57 |
Artax Biopharma, Inc.
Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Belgien | 41 | 67,21% |
Niederlande | 10 | 16,39% |
Vereinigte Staaten | 8 | 13,11% |
Kanada | 2 | 3,28% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Andre Hoekema
- Persönliches Netzwerk